{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-286957","form_type":"8-K","ticker":"TNYA","cik":"0001858848","company_name":"Tenaya Therapeutics, Inc.","filed_at":"2026-06-29T13:00:16+00:00","discovered_at":"2026-06-29T13:01:01.305989+00:00","generated_at":"2026-06-29T13:01:14.602810+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tenaya Therapeutics appoints Eric Hyllengren as CFO effective July 13, 2026","bullets":["Eric Hyllengren joins as CFO; previously CFO at Zura Bio, CFO/COO at Atara Biotherapeutics.","Hyllengren receives $490k base salary, 40% target bonus, option to purchase 1.65M shares.","SVP Finance Tomohiro Higa to retire in Q3 2026; will remain as consultant for transition.","CEO Faraz Ali and Tomohiro Higa cease as interim PFO and acting PAO as of July 13.","Hyllengren brings 20+ years experience in biotech finance, capital markets, corporate strategy."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-286957","json":"https://secwatch.observer/filing/0001193125-26-286957.json","markdown":"https://secwatch.observer/filing/0001193125-26-286957.md","text":"https://secwatch.observer/filing/0001193125-26-286957.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858848/000119312526286957/0001193125-26-286957-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858848/000119312526286957/tnya-20260629.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T13:01:14.602810+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}